ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Acquired by Sei Investments Co.

Sei Investments Co. boosted its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 147.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 527,272 shares of the biotechnology company’s stock after acquiring an additional 314,013 shares during the quarter. Sei Investments Co. owned 0.22% of ADMA Biologics worth $9,043,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Larson Financial Group LLC purchased a new stake in ADMA Biologics during the 3rd quarter worth about $31,000. GAMMA Investing LLC raised its position in shares of ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 967 shares in the last quarter. National Bank of Canada FI acquired a new position in ADMA Biologics in the third quarter valued at approximately $35,000. Vision Financial Markets LLC purchased a new position in ADMA Biologics in the fourth quarter valued at approximately $51,000. Finally, AlphaQuest LLC acquired a new stake in ADMA Biologics during the fourth quarter worth approximately $84,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 target price on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Price Performance

Shares of NASDAQ:ADMA opened at $20.26 on Monday. ADMA Biologics, Inc. has a one year low of $5.90 and a one year high of $23.64. The stock has a market capitalization of $4.79 billion, a price-to-earnings ratio of 72.36 and a beta of 0.60. The company has a 50-day simple moving average of $17.13 and a 200-day simple moving average of $18.16. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.